Company / Gross Profit per Share
TherapeuticsMD, Inc. Gross Profit per Share History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit per Share
$7.22
FY2023
5-year range
$0.05 / $7.22
FY2019-FY2023
Trend
+5200.5%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Profit per Share changed +5201% YoY in FY2023, a notable deviation from the 8-year average annual change of +676%.
Based on SEC 10-K filings.
7.22 in FY2023 with a 5-year CAGR of +152.7%.
Improved from $0.14 to $7.22 over the past 2 years.
Gross Profit per Share over time
Growth rates
- 3-Year CAGR
- +427.2%
- 5-Year CAGR
- +152.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, gross profit per share increased 5200.5% year-over-year.
- Lowest gross profit per share in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross Profit per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | $7.22 | +5200.5% |
| FY2022 | $0.14 | -5.7% |
| FY2021 | $0.14 | +193.2% |
| FY2020 | $0.05 | -16.2% |
| FY2019 | $0.06 | -16.1% |
| FY2018 | $0.07 | -11.8% |
| FY2017 | $0.08 | +24.6% |
| FY2016 | $0.06 | +35.7% |
| FY2015 | $0.05 | +176.0% |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026